Yichen Zhou

This study identifies that genetic accessibility, not superior fitness, determines the selection of anti-HBs antibody escape variants in patients using in vivo screening.

This study shows that HBV BCP mutations enhance viral replication and alter hepatocyte transcription, linking to specific HCC subtypes.

The paper develops CRISPR-Cas9 delivery methods for primary human hepatocytes to enable efficient gene editing and screening of HBV host factors.

The paper identifies HBV host factors using CRISPR screens and human liver chimeric mice, finding that EXOC1 is antiviral and ZCCHC14 is proviral.